befotinib

Befotinib is a small molecule tyrosine kinase inhibitor. It is designed to target and inhibit the activity of specific receptor tyrosine kinases involved in cancer cell proliferation and survival, particularly the epidermal growth factor receptor (EGFR) family. Befotinib has been investigated primarily for its potential use in treating various cancers, including non-small cell lung cancer (NSCLC). Its mechanism of action involves blocking EGFR signaling pathways, which can lead to reduced tumor growth and increased apoptosis in cancer cells. The drug has been under development by pharmaceutical companies focused on oncology therapeutics.